Harvey Capital Management Inc. Sells 2,533 Shares of argenx SE (NASDAQ:ARGX)

Harvey Capital Management Inc. lessened its position in argenx SE (NASDAQ:ARGX) by 18.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 11,561 shares of the company’s stock after selling 2,533 shares during the quarter. argenx accounts for 1.7% of Harvey Capital Management Inc.’s portfolio, making the stock its 21st largest position. Harvey Capital Management Inc.’s holdings in argenx were worth $7,110,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the company. Advisors Preferred LLC bought a new stake in argenx in the fourth quarter worth about $73,000. Cromwell Holdings LLC raised its holdings in shares of argenx by 73.3% in the third quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock worth $85,000 after buying an additional 66 shares during the period. GAMMA Investing LLC lifted its stake in shares of argenx by 47.5% during the 3rd quarter. GAMMA Investing LLC now owns 174 shares of the company’s stock worth $94,000 after acquiring an additional 56 shares during the last quarter. SG Americas Securities LLC boosted its holdings in argenx by 6.2% during the 4th quarter. SG Americas Securities LLC now owns 358 shares of the company’s stock valued at $220,000 after acquiring an additional 21 shares during the period. Finally, Fulton Bank N.A. bought a new position in argenx in the 4th quarter valued at $226,000. 60.32% of the stock is owned by hedge funds and other institutional investors.

argenx Trading Down 1.6 %

Shares of ARGX opened at $636.02 on Wednesday. The firm has a market cap of $38.64 billion, a PE ratio of -722.75 and a beta of 0.58. argenx SE has a 12 month low of $349.86 and a 12 month high of $678.21. The stock has a fifty day moving average price of $638.28 and a 200-day moving average price of $579.86.

Analyst Ratings Changes

Several analysts have recently weighed in on ARGX shares. Truist Financial reiterated a “buy” rating and set a $700.00 target price (up from $660.00) on shares of argenx in a research report on Tuesday, January 14th. Guggenheim boosted their price objective on shares of argenx from $585.00 to $665.00 and gave the company a “buy” rating in a research report on Friday, November 1st. Wolfe Research raised shares of argenx from a “peer perform” rating to an “outperform” rating and set a $697.00 target price on the stock in a research report on Tuesday, November 12th. Oppenheimer reaffirmed an “outperform” rating and set a $675.00 price target (up previously from $646.00) on shares of argenx in a research note on Thursday, November 21st. Finally, JPMorgan Chase & Co. increased their price objective on argenx from $640.00 to $670.00 and gave the stock an “overweight” rating in a research note on Monday, November 4th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $658.39.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.